The partners will adapt Eukarÿs' C3P3 engineered enzyme tech to work with adeno-associated virus vectors to boost biomanufacturing yields.

Genethon & Eukarÿs enter strategic partnership to develop a breakthrough technology to reduce the biomanufacturing cost of gene therapies: Evry, France Friday, January 24, 2025, ...

EBP1 is low in Alzheimer’s disease brains, hinting at human relevance. “Our study suggests that … preservation of functional EBP1 could be a therapeutic strategy for AD,” the authors noted. The ...

Explore the role of preclinical MRI in studying neurological diseases, with a focus on advanced cellular and molecular ...

Enzymes catalyze nearly all of the chemical reactions that occur in biological systems. Enzymes are generally proteins but also include catalytic DNA and catalytic RNA. As effective biological ...

Understanding bacterial growth mechanisms can potentially help uncover novel drug targets that are crucial for maintaining cellular viability, particularly for bacterial pathogens. In this important ...

As the year unfolds the biotech industry will look closely at these ten first-in-class drugs on track to reach FDA approval ...

This manuscript describes the identification and characterization of 12 specific phosphomimetic mutations in the recombinant full-length human tau protein that trigger tau to form fibrils. This ...

In a finding with implications for one of the most promising cutting-edge medical treatments, researchers evaluated several measurement techniques commonly used in gene therapy.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported ...